Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 4, 2008, Pages 447-450

  Engel, K ^a   Reuter, J ^a   Seiler, C ^a   Mönting, J Schulte ^a   Jakob, T ^a   Schempp, Christoph M ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Erythema index; Skin barrier; Sodium lauryl sulphate; Transepidermal water loss

Indexed keywords

DODECYL SULFATE SODIUM; HYDROCORTISONE; PIMECROLIMUS; PLACEBO;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; EPIDERMIS; ERYTHEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN INFLAMMATION; SKIN IRRITATION; SKIN PENETRATION; SKIN WATER LOSS; VOLUNTEER;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BACK; DERMATITIS, IRRITANT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; OINTMENTS; SODIUM DODECYL SULFATE; SURFACE-ACTIVE AGENTS; TACROLIMUS; TREATMENT OUTCOME; WATER LOSS, INSENSIBLE;

EID: 41149167183     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02477.x     Document Type: Article

References (25)

1. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
2. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-730.
3. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: Meta-analysis of randomized controlled trials. BMJ 2005; 330: 516-524.
4. Ling M, Gottlieb A, Pariser D et al. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. J Dermatolog Treat 2005; 16: 142-148.
5. Luger TA, Bieber T, Meurer M et al. Therapie des atopischen Ekzems mit Calcineurin-Inhibitoren. J Dtsch Dermatol Ges 2005; 5: 385-391.
6. Reitamo S, Wollenberg A, Schöpf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999-1006.
7. Hill C, Rosenberg A. Adverse effects from topical steroids. Cutis 1978; 1: 41-46.
8. Jocher A, Kessler S, Hornstein S, Schulte-Monting J, Schempp CM. The UV erythema test as a model to investigate the anti-inflammatory potency of topical preparations -reevaluation and optimization of the method. Skin Pharmacol Physiol 2005; 18: 234-240.
9. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29-35.
10. Löffler H, Effendy I, Happle R. Natriumlaurylsulfat-Test. Eine nichtinvasive Funktionsprüfung der Hautempfindlichkeit. Hautarzt 1996; 47: 832-838.
11. Frosch PJ, Kurte A, Pilz B. Efficacy of skin barrier creams (III): The repetitive irritation test (RIT) in humans. Contact Dermatitis 1993; 29: 113-118.
12. Gehring W, Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Drug Res 2000; 50: 659-663.
13. Katsarou A, Davoy E, Xenos K, Armenaka M, Theoharides TC. Effect of an antioxidant (quercetin) on sodium-lauryl-sulfate-induced skin irritation. Contact Dermatitis 2000; 42: 85-89.
14. Fuchs M, Schliemann-Willers S, Heinemann C, Elsner P. Tacrolimus enhances irritation in a 5-day human irritancy in vivo model. Contact Dermatitis 2002; 46: 290-294.
15. Agner T, Serup J. Skin reactions to irritants assessed by non-invasive bioengineering methods. Contact Dermatitis 1989; 20: 352-359.
16. Tupker RA, Willis C, Berardesca E et al. Guidelines on sodium lauryl sulfate (SLS) exposure tests. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1997; 36: 53-69.
17. Pinnagoda J, Tupker RA, Agner T, Serup J. Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1990; 22: 164-178.
18. Schempp CM, Muller K, Schulte-Monting J, Schopf E, Simon J. Salt water bathing prior to UVB irradiation leads to a decrease of the minimal erythema dose and an increased erythema index without affecting skin pigmentation. Photochem Photobiol 1999; 69: 341-344.
19. Spergel JM, Nurse N, Taylor P, Parneix Spake A. Effect of topical pimecrolimus on epicutaneous skin testing. J Allergy Clin Immunol 2004; 114: 695-697.
20. Ramsing DW, Agner T. Efficacy of topical corticosteroids on irritant skin reactions. Contact Dermatitis 1995; 32: 293-297.
21. Tsai JC, Shen LC, Sheu HM, Lu CC. Tape stripping and sodium dodecyl sulfate treatment increase the molecular weight cutoff of polyethylene glycol penetration across murine skin. Arch Dermatol Res 2003; 295: 169-174.
22. Lademann J, Otberg N, Richter H et al. Follicular penetration. An important pathway for topically applied substances. Hautarzt 2003; 54: 321-323.
23. Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J. Variations of hair follicle size and distribution in different body sites. J Invest Dermatol 2004; 122: 14-19.
24. Aramaki J, Löffler C, Kawana S, Effendy I, Happle R, Loffler H. Irritant patch testing with sodium lauryl sulphate: Interrelation between concentration and exposure time. Br J Dermatol 2001; 145: 704-708.
25. Van der Valk PG, Maibach HI. Do topical corticosteroids modulate skin irritation in human beings? Assessment by transepidermal water loss and visual scoring. J Am Acad Dermatol 1989; 21: 519-522.